Contribution of sialic acids to integrin α5β1 functioning in melanoma cells

Autor: Kolasińska, Ewa, Janik, Marcelina E. ^*, Lityńska, Anna, Przybyło, Małgorzata

Publikováno v: In Advances in Medical Sciences September 2019 64(2):267-273

A Review on Electroactive Polymers for Waste Heat Recovery.

Autor: Kolasińska, Ewa¹ kolasinska@iel.wroc.pl, Kolasiński, Piotr² piotr.kolasinski@pwr.edu.pl

Publikováno v: Materials (1996-1944). Jun2016, Vol. 9 Issue 6, p485. 15p.

POLYANILINE DOPED WITH ACIDS. METHODS OF SYNTHESIS AND MODIFICATION.

Autor: KOLASIŃSKA, Ewa, MAZUREK, Bolesław

Publikováno v: Prace Instytutu Elektrotechniki; 2016, Vol. 63 Issue 274, p61-69, 9p

A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia.

Autor: Czardybon W; Selvita S.A., Krakow, Poland., Windak R; Selvita S.A., Krakow, Poland., Gołas A; Selvita S.A., Krakow, Poland., Gałęzowski M; Selvita S.A., Krakow, Poland., Sabiniarz A; Selvita S.A., Krakow, Poland., Dolata I; Selvita S.A., Krakow, Poland., Salwińska M; Selvita S.A., Krakow, Poland., Guzik P; Selvita S.A., Krakow, Poland., Zawadzka M; Selvita S.A., Krakow, Poland., Gabor-Worwa E; Selvita S.A., Krakow, Poland., Winnik B; Selvita S.A., Krakow, Poland., Żurawska M; Selvita S.A., Krakow, Poland., Kolasińska E; Selvita S.A., Krakow, Poland., Wincza E; Selvita S.A., Krakow, Poland., Bugaj M; Selvita S.A., Krakow, Poland., Danielewicz M; Selvita S.A., Krakow, Poland., Majewska E; Selvita S.A., Krakow, Poland., Mazan M; Selvita S.A., Krakow, Poland., Dubin G; Malopolska Centre of Biotechnology, Krakow, Poland., Noyszewska-Kania M; Dept. of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Jabłońska E; Dept. of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Szydłowski M; Dept. of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Sewastianik T; Dept. of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Puła B; Dept. of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Szumera-Ciećkiewicz A; Dept. of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Prochorec-Sobieszek M; Dept. of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Mądro E; Dept. of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Lech-Marańda E; Dept. of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.; Dept. of Hematology and Transfusion Medicine, Centre of Postgraduate Medical Education, Marymoncka, Warsaw, Poland., Warzocha K; Dept. of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Tamburini J; Institut Cochin, Département Développement, Reproduction, Cancer, Paris, France.; Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.; Equipe Labellisée, Ligue Nationale Contre le Cancer (LNCC), Paris, France., Juszczyński P; Dept. of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Brzózka K; Selvita S.A., Krakow, Poland.

Publikováno v: Oncotarget [Oncotarget] 2018 Mar 30; Vol. 9 (24), pp. 16917-16931. Date of Electronic Publication: 2018 Mar 30 (Print Publication: 2018).